Funds will help the companies create a platform for the manufacturing and characterization of AAV-based gene therapy vectors.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, ...

The global viral vectors for non-human primates market was valued at USD 145.8 Mn in 2023 and is projected to grow at a CAGR ...

Insect miRNAs can be transferred to their host plants upon feeding. This study shows that a conserved insect microRNA plays a ...

John Roehrig died March 8 after a battle with ALS. During his career, he was on the front lines of the U.S. response to West Nile virus.

Apriori Bio has become the latest Flagship Pioneering-backed biotech to shed staff, cutting 15 workers to leave 21 still ...

The IIT Roorkee study on Efavirenz offers a new avenue for Chikungunya treatment, bringing optimism to patients and doctors ...

Yet, the complexity of scaling viral vector processes to commercial levels and the absence of standardized approaches pose significant challenges for therapy development timelines and productivity.

A vaccine against norovirus, the dreaded “winter vomiting bug”, could be closer than you think: early clinical trials have ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies ...

the director of the CDC's Division of Vector-Borne Diseases in Fort Collins. In the summer of 1999, the CDC — under Roehrig's leadership — was able to confirm that the mystery virus sweeping ...